Really exciting news for Parvus!
We are thrilled to be partnered with Abbvie to develop our Navacim technology as a potential treatment or cure for Autoimmune Disease. https://lnkd.in/gZXtTRds
Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing Navacims™, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus’ mission is to shift the treatment paradigm toward Navacim-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinical. Parvus’ leadership team is experienced in successful drug discovery, development, manufacturing, regulatory approval, and commercialization.
External link for Parvus Therapeutics Inc
800 Dubuque Ave.
South San Francisco, California 94080, US
Really exciting news for Parvus!
We are thrilled to be partnered with Abbvie to develop our Navacim technology as a potential treatment or cure for Autoimmune Disease. https://lnkd.in/gZXtTRds